CytomX stockholders approve amended equity plan adding 4.38M shares; three directors elected

CytomX Therapeutics, Inc.

Stockholders elected three Class I directors: Sean McCarthy (16.4M for), Mani Mohindru (19.7M for), Zhen Su (19.7M for), terms until 2028.
Amended 2015 Equity Plan approved; shares available increase to 6,300,000 from prior pool plus 4,381,320 new shares.
Employee Stock Purchase Plan amended to remove evergreen automatic increase and remove 10-year expiration, now indefinite.
Ratified Ernst & Young as auditor for FY2025; advisory vote on exec compensation approved with ~22.9M for, 5.3M against.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.